000 02771cam a2200349 a 4500
003 EG-GiCUC
005 20250223032446.0
008 191123s2019 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.05.Ph.D.2019.Ma.V
100 0 _aMarwa Ahmed Moffid Allam
245 1 0 _aValidated modern analytical methods for the determination of some pharmaceutical mixtures /
_cMarwa Ahmed Moffid Allam ; Supervised Asmaa Ahmed Elzaher Mohamed , Ehab Farouk Elkady , Hanaa Abdelmonem Hashem
246 1 5 _aطرق تحليلية حديثة متحقق من فاعليتها لتقدير بعض المخاليط الصيدلية
260 _aCairo :
_bMarwa Ahmed Moffid Allam ,
_c2019
300 _a191 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutical Chemistry
520 _aThe aim of this work is to develop simple, accurate and precise methods for the determination of some pharmaceutical mixtures in vitro and in human plasma. The drugs were analyzed in their bulk powder and in their pharmaceutical dosage forms either in combinations or in presence combined drugs were determined in plasma. Drugs investigated include Dapagliflozin (SGLT2 inhibitor),Saxagliptin (DPP-4 inhibitor), Metformin (biguanide), Enalapril (ACE-inhibitor), Perindopril (ACEinhibitor), Ramipril (ACE- inhibitor) Atorvastatin calcium and Rosuvastatin calcium (HMG-CoA reductase inhibitor), Ezetimibe (lipid lowering drug), Clopidogrel (adenosine di-phosphate inhibitor) and Telmisartan (angiotensin II blocker) Two LC-MS/MS bioanalytical methods were proposed for the determination of two pharmaceutical mixtures. First mixture is antidiabetic mixture used in treatment of type II diabetes mellitus consisting of dapagliflozin, saxagliptin and metformin. Second mixture consists of three ACE- inhibitors namely, enalapril, perindopril and ramipril. HPLC is a powerful analytical tool for the separation and analysis of pharmaceutical products. It is incorporated in the plan of the work for the estimation of atorvastatin and rosuvastatin in six binary mixtures with other drugs such as ezetimibe, clopidogrel and telmisartan with optimization and application of Box-Behnken experimental design
530 _aIssued also as CD
653 4 _aAnalytical Methods
653 4 _aCardiovascular diseases
653 4 _aDiabetes
700 0 _aAsmaa Ahmed Elzaher Mohamed ,
_eSupervisor
700 0 _aEhab Farouk Elkady ,
_eSupervisor
700 0 _aHanaa Abdelmonem Hashem ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c75420
_d75420